Grünenthal acquires testosterone treatment NebidoTM from Bayer
Aachen, Germany (ots) - - Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. - NebidoTM is the gold standard for the treatment ofmale hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide. - Grünenthal has invested over € 2 billion in successful M&A ...
more